| scholarly article | Q13442814 |
| P50 | author | Stephan A Grupp | Q104495066 |
| P2093 | author name string | Robert H Vonderheide | |
| Barbara A Vance | |||
| Christina M Coughlin | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 2046-2054 | |
| P577 | publication date | 2003-11-20 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy | |
| P478 | volume | 103 |
| Q56967539 | Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses |
| Q34909225 | Acute and chronic B cell depletion disrupts CD4+ and CD8+ T cell homeostasis and expansion during acute viral infection in mice |
| Q35146131 | Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression |
| Q34243887 | Anti-GD2 Strategy in the Treatment of Neuroblastoma |
| Q34725758 | Antibody-based immunotherapy in high-risk neuroblastoma |
| Q64913188 | B Cell-Based Cancer Immunotherapy. |
| Q42969728 | B cell-regulated immune responses in tumor models and cancer patients |
| Q33632113 | B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment |
| Q35444346 | B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. |
| Q37069120 | B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice |
| Q44945891 | B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. |
| Q33684762 | B cells inhibit the antitumor immunity against an established murine fibrosarcoma |
| Q37928542 | B lymphocytes as effector cells in the immunotherapy of cancer |
| Q48371221 | CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides. |
| Q36022324 | CD40 ligand induces RIP1-dependent, necroptosis-like cell death in low-grade serous but not serous borderline ovarian tumor cells. |
| Q34014497 | CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma |
| Q38113268 | CD40-activated B cells as antigen-presenting cells: the final sprint toward clinical application |
| Q37336918 | CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. |
| Q34145881 | CD40-activated B cells can efficiently prime antigen-specific naïve CD8+ T cells to generate effector but not memory T cells |
| Q43406455 | CD40-activated B cells contribute to mesothelioma tumor regression. |
| Q42742311 | CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants |
| Q34080118 | Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. |
| Q34880734 | Characterization of the ribonuclease activity on the skin surface |
| Q33959343 | Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers |
| Q41773067 | Complement opsonization enhances friend virus infection of B cells and thereby amplifies the virus-specific CD8+ T cell response |
| Q39966752 | Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia |
| Q37273700 | Design of CD40 agonists and their use in growing B cells for cancer immunotherapy |
| Q33785850 | Detailed kinetics of the direct allo-response in human liver transplant recipients: new insights from an optimized assay |
| Q53534873 | Efficient antitumor immunity in a murine colorectal cancer model induced by CEA RNA-electroporated B cells. |
| Q49039662 | Efficient gene transfer in CLL by mRNA electroporation. |
| Q37718429 | Efficient generation of antigen-specific CTLs by the BAFF-activated human B Lymphocytes as APCs: a novel approach for immunotherapy |
| Q50035982 | Electroporation of mRNA as Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins |
| Q34105724 | Enhancing T Cell Immune Responses by B Cell-based Therapeutic Vaccine Against Chronic Virus Infection. |
| Q40454655 | Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells. |
| Q35812007 | Ex vivo engineered immune organoids for controlled germinal center reactions |
| Q37271276 | Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting |
| Q35101531 | Human T-cell responses to vaccinia virus envelope proteins. |
| Q37150312 | Immortalized B cells: a neverending source of antigen-presenting cells for vaccines? |
| Q47195254 | Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity |
| Q34616576 | Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors |
| Q40399099 | Immuno-engineered organoids for regulating the kinetics of B-cell development and antibody production. |
| Q27489354 | Immunogenicity of Human Mesenchymal Stem Cells in HLA-Class I-Restricted T-Cell Responses Against Viral or Tumor-Associated Antigens |
| Q36453273 | Immunotherapy of neuroblastoma: present, past and future. |
| Q35971029 | Immunotherapy targets in pediatric cancer |
| Q34541239 | Impact of CD68/(CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer |
| Q36539717 | Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells |
| Q36628925 | In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins |
| Q37086932 | In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy |
| Q37440696 | Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen. |
| Q40441002 | Inflammation enhances the vaccination potential of CD40-activated B cells in mice |
| Q45863477 | Interferon beta adenoviral gene therapy in a patient with ovarian cancer. |
| Q37439998 | Interferon-gamma-dependent infiltration of human T cells into neuroblastoma tumors in vivo. |
| Q60342834 | Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts |
| Q37469720 | Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells |
| Q35842616 | Messenger RNA-based vaccines |
| Q34477358 | Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines |
| Q35936953 | Nucleofection induces transient eIF2α phosphorylation by GCN2 and PERK. |
| Q40002875 | RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma |
| Q36111911 | Regulators of apoptosis: suitable targets for immune therapy of cancer |
| Q34478042 | Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: A preliminary approach for anti-HBV immunotherapy |
| Q35110486 | Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity |
| Q88318271 | The Immune Revolution: A Case for Priming, Not Checkpoint |
| Q41761209 | The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells |
| Q42489904 | The prognostic significance of B lymphocytes in invasive carcinoma of the breast. |
| Q35799028 | The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers |
| Q38026924 | The use of agonistic anti-CD40 therapy in treatments for cancer |
| Q43105000 | Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications |
| Q36413361 | Tumor microenvironment B cells increase bladder cancer metastasis via modulation of the IL-8/androgen receptor (AR)/MMPs signals |
Search more.